Eli Lilly-backed TRex Bio Targets $133M in U.S. IPO

Key Facts

1Biotech firm TRex Bio is aiming to raise up to $133 million through an initial public offering in the United States.

2TRex Bio is backed by pharmaceutical giant Eli Lilly.

Biotech firm TRex Bio is aiming to raise up to $133 million through an initial public offering in the United States. Seeking Alpha reported that the anti-inflammatory drug developer filed details with the SEC on Monday regarding its plan to list on the Nasdaq exchange.

TRex Bio is backed by pharmaceutical giant Eli Lilly and intends to use the IPO proceeds to fund its research and development pipeline. Regarding the strategic partner's market performance, LLY closed at $1,143.12 on October 5, 2026, having reached a session high of $1,165.73 on that date.